Eligibility for treatment of hepatitis C virus infection among young injection drug users in 3 US cities

被引：37

作者：

Hagan, H

Latka, MH

Campbell, JV

Golub, ET

Garfein, RS

Thomas, DA

Kapadia, F

Strathdee, SA

机构：

[1] Natl Dev Inst, Ctr Drug Use & HIV Res, New York, NY 10010 USA

[2] Nat Res Inst, Ctr Drug Use & HIV Res, New York, NY 10010 USA

[3] New York Acad Med, Ctr Urban Epidemiol Studies, New York, NY USA

[4] Publ Hlth Seattle & King Cty, HIV AIDS Epidemiol, Seattle, WA USA

[5] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA

[6] Sch Med, Baltimore, MD USA

[7] Univ Calif San Diego, Sch Med, Dept Family & Prevent Med, San Diego, CA 92103 USA

来源：

CLINICAL INFECTIOUS DISEASES | 2006年 / 42卷 / 05期

关键词：

D O I：

10.1086/499951

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Among 404 injection drug users aged 18-35 who tested positive for hepatitis C virus (HCV) RNA, 96% had conditions that are potentially unwarranted contraindications for HCV treatment ( e. g., problem drinking, moderate-to-severe depression, and recent drug injection). Restrictive eligibility criteria may deny treatment to a large proportion of patients who could benefit from it.

引用

页码：669 / 672

页数：4

共 50 条

[1] Eligibility for treatment of hepatitis C virus infection among young injection drug users in three US cities
Hagan, H
Campbell, J
Garfein, R
Latka, M
Strathdee, S
Thomas, D
Golub, E
HEPATOLOGY, 2005, 42 (04) : 693A - 693A
[2] Eligibility for treatment of hepatitis C virus infection among young injection drug users in 3 US cities. (vol 42, pg 669, 2006)
Hagan, H
Latka, MH
Campbell, JV
Golub, ET
Garfein, RS
Thomas, DA
Kapadia, F
Strathdee, SA
CLINICAL INFECTIOUS DISEASES, 2006, 42 (12) : 1818 - 1818
[3] Prevalence of hepatitis C virus and HIV infection among injection drug users in two Mexican cities bordering the US
White, Emily Faye
Garfein, Richard S.
Brouwer, Kimberly C.
Lozada, Remedios
Ramos, Rebeca
Firestone-Cruz, Michelle
Perez, Saida G.
Magis-Rodriguez, Carlos
Conde-Glez, Carlos J.
Strathdee, Steffanie A.
SALUD PUBLICA DE MEXICO, 2007, 49 (03): : 165 - 172
[4] Age-specific seroprevalence of HIV, hepatitis B virus, and hepatitis C virus infection among injection drug users admitted to drug treatment in 6 US cities
Murrill, CS
Weeks, H
Castrucci, BC
Weinstock, HS
Bell, BP
Spruill, C
Gwinn, M
AMERICAN JOURNAL OF PUBLIC HEALTH, 2002, 92 (03) : 385 - 387
[5] Attribution of Hepatitis C Virus Seroconversion Risk in Young Injection Drug Users in 5 US Cities
Hagan, Holly
Pouget, Enrique R.
Williams, Ian T.
Garfein, Richard L.
Strathdee, Steffanie A.
Hudson, Sharon M.
Latka, Mary H.
Ouellet, Lawrence J.
JOURNAL OF INFECTIOUS DISEASES, 2010, 201 (03): : 378 - 385
[6] Treatment for hepatitis C virus infection among current injection drug users in Australia
Matthews, G
Kronborg, IJ
Dore, GJ
CLINICAL INFECTIOUS DISEASES, 2005, 40 : S325 - S329
[7] Prevalence and incidence of hepatitis C virus infection among young adult injection drug users
Garfein, RS
Doherty, MC
Monterroso, ER
Thomas, DL
Nelson, KE
Vlahov, D
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 1998, 18 : S11 - S19
[8] GB virus C infection among young, HIV-negative injection drug users with and without hepatitis C virus infection
Boodram, B.
Hershow, R. C.
Klinzman, D.
Stapleton, J. T.
JOURNAL OF VIRAL HEPATITIS, 2011, 18 (04) : e153 - e159
[9] Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment
Thorpe, LE
Ouellet, LJ
Hershow, R
Bailey, SL
Williams, IT
Williamson, J
Monterroso, ER
Garfein, RS
AMERICAN JOURNAL OF EPIDEMIOLOGY, 2002, 155 (07) : 645 - 653
[10] Treatment of hepatitis C infection in injection drug users
Backmund, M
Meyer, K
Von Zielonka, M
Eichenlaub, D
HEPATOLOGY, 2001, 34 (01) : 188 - 193

← 1 2 3 4 5 →